SGS Life Sciences Services to host 4th Antwerp Biopharm Seminar on clinical trial solutions
![](/46/pdcnewsitem/03/60/79/SGS.png)
The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
SGS Life Science Services is to host a complimentary Biopharm Day in Antwerp, Belgium. The event, building on the success of previous years’ events, is to be held at the Lindner Hotel, on Thursday, 29 October 2015. The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
Joining SGS Life Science Services experts will be Ingeborg Heirman, Business Development Manager of VIB vzw, who will explain the role VIB plays in bridging academia with pharma/biotech companies and clinical research organizations, to further development of innovative drugs and biomarkers/diagnostic assays; Gary Kay, CEO of Cognitive Research Corporation, who will present on the 2015 FDA Draft Guidance on evaluating drug effects on driving; and Dr Jean François Rossignol, co-founder, Chief Scientific Officer and Chairman of Romark Laboratories, who will present a case study on influenza vaccine development. A tour of SGS Life Science Services’ Clinical Pharmacology Unit will be organized following the closing remarks. “The clinical research field has many challenges and opportunities which face both sponsors and service providers,” commented Jean-Luc Marsat, Business Manager at SGS Life Science Services. “By bringing together our clients and leading industry experts, and sharing experiences and knowledge in an open forum, we aim to give valuable insight into new trends and practices in biopharmaceutical research and development from a wide range of industry perspectives.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance